Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Identifieur interne : 000169 ( Pmc/Corpus ); précédent : 000168; suivant : 000170Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Auteurs : E. Munzone ; A. Giobbie-Hurder ; B. A. Gusterson ; E. Mallon ; G. Viale ; B. Thürlimann ; B. Ejlertsen ; G. Macgrogan ; F. Bibeau ; G. Lelkaitis ; K. N. Price ; R. D. Gelber ; A. S. Coates ; A. Goldhirsch ; M. ColleoniSource :
- Annals of Oncology [ 0923-7534 ] ; 2015.
Abstract
In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.
Url:
DOI: 10.1093/annonc/mdv391
PubMed: 26387144
PubMed Central: 4658543
Links to Exploration step
PMC:4658543Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name><affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name><affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name><affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name><affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name><affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name><affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name><affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></nlm:aff></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26387144</idno><idno type="pmc">4658543</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658543</idno><idno type="RBID">PMC:4658543</idno><idno type="doi">10.1093/annonc/mdv391</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000169</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name><affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name><affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name><affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name><affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name><affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name><affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name><affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></nlm:aff></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author></analytic><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Oncol</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-id journal-id-type="hwp">annonc</journal-id><journal-title-group><journal-title>Annals of Oncology</journal-title></journal-title-group><issn pub-type="ppub">0923-7534</issn><issn pub-type="epub">1569-8041</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26387144</article-id><article-id pub-id-type="pmc">4658543</article-id><article-id pub-id-type="doi">10.1093/annonc/mdv391</article-id><article-id pub-id-type="publisher-id">mdv391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Breast Tumors</subject></subj-group></subj-group></article-categories><title-group><article-title>Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Munzone</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="mdv391_af1">1</xref><xref ref-type="corresp" rid="mdv391_cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdv391_af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gusterson</surname><given-names>B. A.</given-names></name><xref ref-type="aff" rid="mdv391_af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mallon</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="mdv391_af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Viale</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thürlimann</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="mdv391_af6">6</xref><xref ref-type="aff" rid="mdv391_af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ejlertsen</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="mdv391_af8">8</xref></contrib><contrib contrib-type="author"><name><surname>MacGrogan</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bibeau</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="mdv391_af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Lelkaitis</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>K. N.</given-names></name><xref ref-type="aff" rid="mdv391_af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>R. D.</given-names></name><xref ref-type="aff" rid="mdv391_af2">2</xref><xref ref-type="aff" rid="mdv391_af13">13</xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="mdv391_af14">14</xref><xref ref-type="aff" rid="mdv391_af15">15</xref></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdv391_af16">16</xref></contrib><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="mdv391_af1">1</xref></contrib><on-behalf-of>for the International Breast Cancer Study Group and the BIG 1-98 Collaborative Group</on-behalf-of><aff id="mdv391_af1"><label>1</label><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff><aff id="mdv391_af2"><label>2</label><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></aff><aff id="mdv391_af3"><label>3</label><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></aff><aff id="mdv391_af4"><label>4</label><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></aff><aff id="mdv391_af5"><label>5</label><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff><aff id="mdv391_af6"><label>6</label><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></aff><aff id="mdv391_af7"><label>7</label><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></aff><aff id="mdv391_af8"><label>8</label><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></aff><aff id="mdv391_af9"><label>9</label><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></aff><aff id="mdv391_af10"><label>10</label><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></aff><aff id="mdv391_af11"><label>11</label><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></aff><aff id="mdv391_af12"><label>12</label><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></aff><aff id="mdv391_af13"><label>13</label><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></aff><aff id="mdv391_af14"><label>14</label><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></aff><aff id="mdv391_af15"><label>15</label><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></aff><aff id="mdv391_af16"><label>16</label><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff></contrib-group><author-notes><corresp id="mdv391_cor1"><label>*</label><italic>Correspondence to:</italic> Dr Elisabetta Munzone, Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel: +39-02-57489502; E-mail: <email>elisabetta.munzone@ieo.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 12 months and
0 days and was based on the
<volume>26</volume><issue>12</issue><fpage>2442</fpage><lpage>2449</lpage><history><date date-type="received"><day>9</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>3</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:href="mdv391.pdf"></self-uri><abstract abstract-type="precis"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p></abstract><abstract><sec><title>Background</title><p>We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.</p></sec><sec><title>Patients and methods</title><p>The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (<italic>N</italic> = 100), tubular/cribriform (<italic>N</italic> = 83), ductal (<italic>N</italic> = 3257), and other (<italic>N</italic> = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.</p></sec><sec><title>Results</title><p>Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94–11.7; <italic>P</italic> = 0.06].</p></sec><sec><title>Conclusions</title><p>Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.</p></sec><sec><title>Clinicaltrials.gov</title><p>NCT00004205.</p></sec></abstract><kwd-group><kwd>letrozole</kwd><kwd>tamoxifen</kwd><kwd>mucinous</kwd><kwd>tubular</kwd><kwd>cribriform</kwd><kwd>breast cancer</kwd></kwd-group><funding-group><award-group id="funding-1"><funding-source>Novartis <named-content content-type="funder-id">http://dx.doi.org/10.13039/100004336</named-content></funding-source></award-group><award-group id="funding-2"><funding-source>IBCSG: Swedish Cancer Society,</funding-source></award-group><award-group id="funding-3"><funding-source>US National Institute of Health</funding-source></award-group><award-group id="funding-4"><funding-source>Foundation for Clinical Cancer Research of Eastern Switzerland</funding-source></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:4658543
|texte= Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:26387144" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |